Zacks Investment Research cut shares of Homology Medicines (NASDAQ:FIXX) from a hold rating to a sell rating in a research note published on Thursday morning.
According to Zacks, “Homology Medicines Inc. is a genetic medicines company. Its platform offers human hematopoietic stem cell derived adeno-associated virus vectors to treat disease-causing mutations through gene correction, insertion and knockout. Homology Medicines Inc. is based in BEDFORD MA. “
Other research analysts have also recently issued reports about the company. ValuEngine cut Homology Medicines from a buy rating to a hold rating in a research note on Friday, December 7th. Canaccord Genuity began coverage on Homology Medicines in a research note on Monday, January 7th. They set a buy rating and a $37.00 target price for the company. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company’s stock. The company currently has an average rating of Buy and a consensus target price of $27.75.
FIXX stock opened at $24.87 on Thursday. Homology Medicines has a 12-month low of $15.07 and a 12-month high of $26.50.
Homology Medicines (NASDAQ:FIXX) last posted its quarterly earnings data on Tuesday, November 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by ($0.03). The company had revenue of $0.95 million during the quarter. Sell-side analysts anticipate that Homology Medicines will post -1.49 EPS for the current year.
In related news, Director Kush Parmar sold 15,575 shares of the business’s stock in a transaction on Monday, December 10th. The stock was sold at an average price of $26.01, for a total transaction of $405,105.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Ventures Iv L.P. 5Am sold 29,682 shares of the business’s stock in a transaction on Friday, November 23rd. The stock was sold at an average price of $20.04, for a total value of $594,827.28. The disclosure for this sale can be found here. Insiders have sold a total of 571,157 shares of company stock valued at $11,623,113 over the last three months.
Large investors have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp acquired a new position in shares of Homology Medicines during the 2nd quarter worth about $558,000. BlackRock Inc. acquired a new position in shares of Homology Medicines during the 2nd quarter worth about $10,831,000. JPMorgan Chase & Co. boosted its position in shares of Homology Medicines by 29.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,251,444 shares of the company’s stock worth $51,468,000 after acquiring an additional 516,156 shares in the last quarter. Schwab Charles Investment Management Inc. acquired a new position in shares of Homology Medicines during the 2nd quarter worth about $998,000. Finally, Global Thematic Partners LLC acquired a new position in shares of Homology Medicines during the 3rd quarter worth about $3,081,000. 53.41% of the stock is owned by institutional investors and hedge funds.
About Homology Medicines
Homology Medicines, Inc, a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.
Further Reading: Market Capitalization and Individual Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Homology Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Homology Medicines and related companies with MarketBeat.com's FREE daily email newsletter.